Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma

被引:119
作者
Bullen, WW [1 ]
Miller, RA [1 ]
Hayes, RN [1 ]
机构
[1] Warner Lambert Co, Parke Davis Pharmaceut Res Div, Ann Arbor, MI 48105 USA
关键词
D O I
10.1016/S1044-0305(98)00118-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A liquid chromatographic/mass spectrometric method to quantitate atorvastatin (AT) and its active metabolites ortho-hydroxy (o-AT) and para-hydroxy (p-AT) atorvastatin in human, dog, and rat plasma was validated. The method consisted of washing plasma samples at high pH with diethyl ether and subsequently extracting the analytes and two internal standards, [d(5)]-atorvastatin ([d(5)]-AT) and [d(5)]-ortho-hydroxy atorvastatin ([d(5)]-o-AT), from acidified plasma by using diethyl ether. The ether layer was evaporated to dryness and the residue reconstituted in ammonium acetate (20 mM, pH 4.0)-acetonitrile-isopropanol (60:40:1, v/v/v). Chromatographic separation of analytes was achieved by using a YMC J'Sphere H80 (C-18) 150 x 2 mm, 4 mu m particle size, column with a mobile phase consisting of acetonitrile-0.1% acetic acid, (70:30, v/v). Analytes were detected by using MS/MS. Sample introduction and ionization was by electrospray ionization in the positive ion mode. The method proved suitable for routine quantitation of AT, o-AT, and p-AT over the concentration range of 0.250 to 25.0 ng/mL. Approximate retention time ranges of p-AT, o-AT, [d(5)]-o-AT, AT, and [d(5)]-AT were 2.27 +/- 0.21, 3.36 +/- 0.23, 3.54 +/- 0.46, 4.12 +/- 0.61, and 4.65 +/- 0.65 min, respectively. No peaks interfering with quantitation were observed throughout the validation processes. Mean recoveries of AT, o-AT, and p-AT from plasma ranged 100%-107%, 70.6%-104%, and 47.6%-85.6%, respectively. Mean recoveries of the [d(5)]-AT and [d(5)]-o-AT internal standards ranged 98.0%-99.9% and 97.3%-97.9%, respectively. Interassay precision, based on the percent relative deviation for replicate quality controls for AT, o-AT, and p-AT, was less than or equal to 7.19%, 8.28%, and 12.7%, respectively. Interassay accuracy for AT, o-AT, and p-AT was +/-10.6%, 5.86%, and 15.8%, respectively. AT, o-AT, and p-AT in human, dog, and rat plasma quality controls were stable to three freeze-thaw cycles. AT, o-AT, and p-AT were stable frozen for 127, 30 and 270 days in human, dog, and rat plasma quality control samples, respectively. Human plasma quality control samples containing AT, o-AT, and p-AT were stable for at least 4 days at ambient room temperature and 37 degrees C. The lower Limit of quantitation for all analytes was 0.250 ng/mL for a 1.0-mL sample aliquot. (J Am Soc Mass Spectrom 1999, 10, 55-66) (C) 1999 American Society for Mass Spectrometry.
引用
收藏
页码:55 / 66
页数:12
相关论文
共 16 条
[1]   SIMULTANEOUS DETERMINATION OF TENIDAP AND ITS STABLE ISOTOPE ANALOG IN SERUM BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY ATMOSPHERIC-PRESSURE CHEMICAL IONIZATION TANDEM MASS-SPECTROMETRY [J].
AVERY, MJ ;
MITCHELL, DY ;
FALKNER, FC ;
FOUDA, HG .
BIOLOGICAL MASS SPECTROMETRY, 1992, 21 (07) :353-357
[2]   Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia [J].
BakkerArkema, RG ;
Davidson, MH ;
Goldstein, RJ ;
Davignon, J ;
Isaacsohn, JL ;
Weiss, SR ;
Keilson, LM ;
Brown, WV ;
Miller, VT ;
Shurzinske, LJ ;
Black, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02) :128-133
[3]  
BEVINGTON PR, 1969, DATA REDUCTION ERROR, P105
[4]   Quantitation of SR 27417 in human plasma using electrospray liquid chromatography tandem mass spectrometry: A study of ion suppression [J].
Buhrman, DL ;
Price, PI ;
Rudewicz, PJ .
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 1996, 7 (11) :1099-1105
[5]   RAPID-DETERMINATION OF METHANDROSTENOLONE IN EQUINE URINE BY ISOTOPE-DILUTION LIQUID-CHROMATOGRAPHY TANDEM MASS-SPECTROMETRY [J].
EDLUND, PO ;
BOWERS, L ;
HENION, J ;
COVEY, TR .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 497 :49-57
[6]  
Hayes R., 1996, Pharmaceutical Research (New York), V13, pS47
[7]  
HSU SH, 1994, METHODOLOGICAL SURVE, V23, P169
[8]  
Le Couteur D. G., 1996, P AUSTR SOC CLIN EXP, V3, P153
[9]   REDUCTION OF LDL CHOLESTEROL BY 25-PERCENT TO 60-PERCENT IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA BY ATORVASTATIN, A NEW HMG-COA REDUCTASE INHIBITOR [J].
NAWROCKI, JW ;
WEISS, SR ;
DAVIDSON, MH ;
SPRECHER, DL ;
SCHWARTZ, SL ;
LUPIEN, PJ ;
JONES, PH ;
HABER, HE ;
BLACK, DM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (05) :678-682
[10]  
REID E, 1994, METHODOL SURV BIOANA, V23, P157